

ONCOLOGY PORTFOLIO - Approved Products & Pipeline

INN /COMPOUND	CLASS	TARGET & MODALITY	INDICATION OR DISEASE	Discovery	Preclinical	Phase I	Phase II	Phase III	In Registration	Approved*
Vinorelbine	Chemotherapy	Vinca Alkaloid	 Advanced BREAST CANCER as monotherapy or in combination with other agents							
		Vinca Alkaloid	 Advanced NSCLC as monotherapy or in combination with other chemotherapies							
		Vinca Alkaloid	 Adjuvant treatment of NSCLC in combination with platinum-based chemotherapy							
Vinflunine	Chemotherapy	Vinca Alkaloid	 Advanced or metastatic transitional-cell carcinoma of the UROTHELIAL tract							
Neratinib ¹	Targeted therapy	Pan-HER inhibitor	 HER2 amplified / overexpressed / HR+ early BREAST CANCER (extended adjuvant post trastuzumab based therapy)							
Tabelecleucel ²	Cell therapy	Allogeneic T-cell immunotherapy	 Epstein-Barr virus associated post-transplant lymphoproliferative disease (EBV + PTLD)							
Encorafenib ³ / Binimetinib ⁴ (± other agents)	Targeted therapy	BRAF inhibitor + MEK inhibitor	 Unresectable or metastatic <i>BRAF</i> ^{V600} -mutant MELANOMA							
		BRAF inhibitor + MEK inhibitor	 Metastatic <i>BRAF</i> ^{V600E} -mutant NSCLC ⁵							
		BRAF inhibitor	 Metastatic <i>BRAF</i> ^{V600E} -mutant CRC after prior systemic therapy							
		BRAF inhibitor	 Metastatic <i>BRAF</i> ^{V600E} -mutant CRC in first-line treatment ⁵							
		BRAF inhibitor + MEK inhibitor	 Metastatic <i>BRAF</i> ^{V600E} -mutant NSCLC in Chinese population - OCEAN study							
Exarafenib ⁶	Targeted therapy	Pan-RAF small molecule inhibitor	 <i>NRAS</i> mutant MELANOMA and other <i>BRAF</i> / <i>NRAS</i> mutant solid tumors							
PFL-721 ⁷	Targeted therapy	Mutant-selective EGFR-exon 20 small molecule inhibitor	 NSCLC with <i>EGFR</i> exon 20 insertion mutation							
PFL-241 ⁷	Targeted therapy	Mutant-selective 4 th generation EGFR small molecule inhibitor	 NSCLC with <i>EGFR</i> exon 19/21 + C797S mutations							
PFL-002 ⁸	Targeted therapy	Anti-cMET antibody degrader	 NSCLC / solid tumors with mutations or amplification of <i>MET</i>							
Not-disclosed ⁹	Targeted therapy	Multiple targets	 ONCOLOGY							

*Approved at least by EMA. Vinorelbine was approved by National Health Authorities (before EU centralized procedure implementation).
1.Commercialized in partnership with Puma Biotechnology. 2.Commercialized in partnership with Atara Biotherapeutics. 3.Encorafenib + cetuximab is approved for *BRAF*^{V600E}-mutant mCRC, after prior systemic therapy. Encorafenib + binimetinib is approved for unresectable or metastatic *BRAF*-mutant melanoma, in adult patients. 4.Developed and launched in partnership with Array Biophama (partnered with Pfizer since 2020). 5.Clinical development under Pfizer sponsorship. 6.Originated by Kinnate Biopharma Inc. Investigational Pan-RAF Inhibitor, Exarafenib, acquired by Pierre Fabre Laboratories. 7.Originated by Scorpion Therapeutics acquired by Pierre Fabre Laboratories. 8.Originated by Vertical Bio AG, acquired by Pierre Fabre Laboratories. 9.Discovery partnership with Vernalis Lt and RedRidge Bio.

This display includes ongoing clinical trials for both approved and investigational compounds. Inclusion in this display does not imply regulatory approval for these compounds or all indications.
Products should be used in accordance with their prescribing information. Information about the trials can be found at www.ClinicalTrials.gov